Why the study?
Do different formulations of furosemide differ in bioavailability and natriuretic response in elderly patients?
Do different formulations of furosemide differ in bioavailability and natriuretic response in elderly patients?
Furosemide exhibits high intra- and inter-patient variability in bioavailability that overwhelms any differences between approved formulations, meaning switching brands will not predictably change response.
No takes yet. Share an insight, caveat, or question.
Switching furosemide formulations will not predictably alter bioavailability in elderly patients; confirms high intra- and inter-patient variability as the dominant factor.
Murray et al. (1997) studied this question.
Synapse has enriched 3 closely related papers on similar clinical questions. Consider them for comparative context: